Analyst consensus rating
Immix Biopharma Analyst Rating: none
Direct answer
Immix Biopharma's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.30.
Forecast evidence checked October 17, 2026.
Get free Immix Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.98
- Average price target
- $24.30
- High price target
- $30.00
- Low price target
- $17.40
- Low target gap
- +118%
- Target upside
- +204.5%
- High target gap
- +275.9%
- Target range width
- 157.9%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immix Biopharma?
Immix Biopharma has a verified none consensus. The same dataset has an average price target of $24.30.
How far are Immix Biopharma's low and high targets from the recorded price?
The low target implies +118%, while the high target implies +275.9%.
How many analysts are included in Immix Biopharma's consensus?
The verified consensus includes 8 analysts.
How is Immix Biopharma's target upside or downside calculated?
The average target of $24.30 is divided by the recorded price of $7.98, then one is subtracted to produce +204.5%. This does not guarantee a future return.
When was Immix Biopharma's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.